Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$41.15 USD
-0.76 (-1.81%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $41.14 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TARS 41.15 -0.76(-1.81%)
Will TARS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TARS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARS
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
TARS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Declining Medical Customers Affect Cigna's Q1 Earnings?
Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High?
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline
Other News for TARS
Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q2 2025 Result
Short Report: Grindr shorts at record highs as CFO quits before earnings
Deep Track Capital, LP Increases Stake in Tarsus Pharmaceuticals Inc
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 | TARS ...
ClearBridge Small Cap Strategy Q2 2025 Commentary